Clinical Trials Logo

Epirubicin clinical trials

View clinical trials related to Epirubicin.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT01848197 Not yet recruiting - Breast Cancer Clinical Trials

Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer

PATEN
Start date: May 2013
Phase: N/A
Study type: Interventional

RATIONALE: Adjuvant chemotherapy has been proven to reduce significantly the risk for relapse and death in women with operable breast cancer.In the North American Inter-Group factorial trial design (CALGB 9741) the concept of dosedense adjuvant chemotherapy was further tested in patients with node-positive breast cancer.Weekly paclitaxel after standard adjuvant chemotherapy with epirubicin and cyclophosphamide improves disease-free and overall survival in women with breast cancer.Investigators asked if dose-dense 2-week intertreatment intervals (supported by the use of granulocyte-colony stimulating factor) were better than the conventional inconvenient weekly intervals.